The Relationship Between Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor 2 Expression of Breast Cancer and the Retention Index in Dual Phase 18F-FDG PET/CT

被引:13
|
作者
Moon H. [1 ]
Noh W.C. [2 ]
Kim H.-A. [2 ]
Kim E.-K. [2 ]
Park K.W. [3 ]
Lee S.S. [4 ,5 ]
Choi J.H. [1 ]
Han K.W. [1 ]
Byun B.H. [1 ]
Lim I. [1 ]
Kim B.I. [1 ]
Choi C.W. [1 ]
Lim S.M. [1 ]
机构
[1] Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), 75, Nowon-ro, Nowon-gu, Seoul
[2] Department of Surgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul
[3] Department of Radiology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul
[4] National Radiation Emergency Medical Center, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul
[5] Department of Pathology, Korea Cancer Center Hospital, Seoul
关键词
Breast cancer; Dual phase; Estrogen receptor; Human epidermal growth factor receptor 2; Positron emission tomography; Retention index;
D O I
10.1007/s13139-016-0412-2
中图分类号
学科分类号
摘要
Purpose: This study investigates the correlation of retention index (RI) using the dual phase FDG PET/CT scan with the breast cancer biomarkers. Methods: A total of 55 patients with breast cancer underwent dual phase FDG PET/CT scans (60 and 120 min after FDG injection) before treatment. SUVmax and SUVmean of the primary breast tumors were measured, then the percent change of SUVmax and SUVmean between the two scans were calculated, and denoted as RImax and RImean, respectively. After the surgical resection of the breast tumor, the status of biomarkers (ER, PR, and HER-2) was evaluated in the postsurgical specimen. Results: RImean was significantly higher in ER (−) (median, 16.2; IQR, 10.8–21.0) or HER-2 (+) (median, 16.1; IQR, 10.7–21.6) tumors than in ER (+) tumors (median, 9.9; IQR, 5.5–15.3) or HER-2 (−) tumors (median, 10.5; IQR, 5.5–16.1). However, there were no significant differences of SUVmax or RImax according to the ER or HER-2 status. There were no significant differences of any PET parameters between PR (+) and PR (−) tumors. Based off ROC curve analyses, RImean predicted the ER (+) tumors (AUC, 0.699; p = 0.006), and HER-2 (+) tumors (AUC, 0.674; p = 0.022), but not the PR (+) tumors. However, neither SUVmax nor RImax predicted ER (+), PR (+), or HER-2 (+) tumors. Conclusions: Retention index of SUVmean can reflect the ER and HER-2 status of breast cancers. Higher retention index of SUVmean might associate with lower ER expression and higher HER-2 expression. © 2016, Korean Society of Nuclear Medicine.
引用
收藏
页码:246 / 254
页数:8
相关论文
共 50 条
  • [1] Positron Emission Mammography: Correlation of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Status and 18F-FDG
    Wang, Carolyn L.
    MacDonald, Lawrence R.
    Rogers, James V.
    Aravkin, Aleksandr
    Haseley, David R.
    Beatty, J. David
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2011, 197 (02) : W247 - W255
  • [2] Relationship between the expression of oestrogen receptor and progesterone receptor and 18F-FDG uptake in endometrial cancer
    Wu, Chunhua
    Chen, Ruohua
    Xu, Lian
    Chen, Yumei
    Wang, Yining
    Huang, Gan
    Liu, Jianjun
    AGING-US, 2020, 12 (13): : 12921 - 12929
  • [3] Association of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression with Breast Cancer Metastasis in Iran
    Jafari, Seyed Hamed
    Jahanmir, Armaghan
    Bahramvand, Yaser
    Tahmasebi, Sedigheh
    Dallaki, Manoochehr
    Nasrollahi, Elham
    IRANIAN JOURNAL OF MEDICAL SCIENCES, 2022, 47 (01) : 40 - 47
  • [4] Correlation between hormonal receptor status/human epidermal growth factor receptor 2 overexpression and 18F-FDG uptake in patients with breast cancer
    Choi, Yun Jung
    Jeong, Yong Hyu
    Kim, Hyun Jeong
    Lee, Jae-hoon
    Cho, Arthur
    Yun, Mijin
    Lee, Jong Doo
    Kang, Won Jun
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [5] Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Expression Rates in Invasive Breast Carcinoma
    Mais, Daniel D.
    Nazarullah, Alia N.
    Guidi, Anthony J.
    Dintzis, Suzanne
    Blond, Barbara J.
    Long, Thomas A.
    Coulter, Suzanne N.
    Brown, Richard W.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2025, 149 (01) : 8 - 13
  • [6] Expression of Estrogen, Progesterone Receptors, and Human Epidermal Growth Factor Receptor 2 in Women With Breast Cancer
    Mlole, Angela
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2019, 152 : S89 - S89
  • [7] 18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
    Benz, Matthias R.
    Herrmann, Ken
    Walter, Franziska
    Garon, Edward B.
    Reckamp, Karen L.
    Figlin, Robert
    Phelps, Michael E.
    Weber, Wolfgang A.
    Czernin, Johannes
    Allen-Auerbach, Martin S.
    JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (11) : 1684 - 1689
  • [8] Expressional Correlation of Human Epidermal Growth Factor Receptor 2, Estrogen/Progesterone Receptor and Protein 53 in Breast Cancer
    Panahi, Marzieh
    Saki, Najmaldin
    Ashourzadeh, Sara
    Rahim, Fakher
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (06) : 3699 - 3703
  • [9] Advances in Variations of Estrogen Receptor, Progesterone Receptor and Human Epidermal Growth Factor Receptor-2 Status in Metastatic Breast Cancer
    Yuan Yuan
    Zhang Lili
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2013, 1 (02): : 55 - 60
  • [10] Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer
    Kim, HJ
    Cui, XJ
    Hilsenbeck, SG
    Lee, AV
    CLINICAL CANCER RESEARCH, 2006, 12 (03) : 1013S - 1018S